Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Interventional Institute of Zhengzhou University, Zhengzhou, China.
Front Immunol. 2022 Jan 24;13:809761. doi: 10.3389/fimmu.2022.809761. eCollection 2022.
In recent years, immunotherapy has become a hot spot in the treatment of tumors. As an emerging treatment, it solves many problems in traditional cancer treatment and has now become the main method for cancer treatment. Although immunotherapy is promising, most patients do not respond to treatment or develop resistance. Therefore, in order to achieve a better therapeutic effect, combination therapy has emerged. The combination of immune checkpoint inhibition and epigenetic therapy is one such strategy. In this review, we summarize the current understanding of the key mechanisms of how epigenetic mechanisms affect cancer immune responses and reveal the key role of epigenetic processes in regulating immune cell function and mediating anti-tumor immunity. In addition, we highlight the outlook of combined epigenetic and immune regimens, particularly the combination of immune checkpoint blockade with epigenetic agents, to address the limitations of immunotherapy alone.
近年来,免疫疗法已成为肿瘤治疗的热点。作为一种新兴的治疗方法,它解决了传统癌症治疗中的许多问题,现已成为癌症治疗的主要方法。尽管免疫疗法前景广阔,但大多数患者对治疗无反应或产生耐药性。因此,为了达到更好的治疗效果,联合治疗应运而生。免疫检查点抑制与表观遗传治疗的联合就是这样一种策略。在这篇综述中,我们总结了目前对表观遗传机制如何影响癌症免疫反应的关键机制的理解,并揭示了表观遗传过程在调节免疫细胞功能和介导抗肿瘤免疫方面的关键作用。此外,我们还强调了联合表观遗传和免疫方案的前景,特别是免疫检查点阻断与表观遗传药物的联合,以解决单独免疫疗法的局限性。